# Study of RP-6306 With Gemcitabine in Advanced Solid Tumors

Source: https://onco.cc/trials/nct05147272/  
OnCo record `nct05147272` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Lunresertib run by Debiopharm International SA, terminated.

## Summary

Study of RP-6306 With Gemcitabine in Advanced Solid Tumors is a phase 1 interventional study registered as NCT05147272 by Debiopharm International SA, with 67 participants enrolled, started 2021-12-16. Conditions recorded: Adult Solid Tumor. Interventions recorded: RP-6306 (oral PKMYT1 inhibitor).

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05147272
- Phase: 1
- Setting: Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination With Gemcitabine for the Treatment of Advanced Solid Tumors (MAGNETIC Study)
- Sponsor: Debiopharm International SA
- Enrolled: 67

## Sources

- ClinicalTrials.gov NCT05147272: https://clinicaltrials.gov/study/NCT05147272

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Lunresertib](https://onco.cc/drugs/lunresertib/)
- companies: [Debiopharm](https://onco.cc/companies/debiopharm/), [Repare Therapeutics](https://onco.cc/companies/repare-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05147272.json